<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tibolone (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tibolone (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tibolone (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="129195" href="/d/html/129195.html" rel="external">see "Tibolone (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F54858525"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tibella</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F20321340"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Steroid, Synthetic</li></ul></div>
<div class="block doa drugH1Div" id="F20321380"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause: </b>
<b>Oral:</b> 2.5 mg once daily; maximum dose: 2.5 mg/day. Initiate ≥1 year after naturally occurring menopause, or immediately in patients with surgical menopause or those being treated with gonadotropin-releasing hormone (GnRH) analogues.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from other menopausal hormone therapy:</i> If on sequential menopausal hormone therapy (MHT), initiate tibolone 1 day after the completion of the current treatment cycle. If on continuous-combined MHT, may initiate tibolone therapy at any time. <b>Note:</b> A separate progestogen should not be added to tibolone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> If &gt;12 hours has elapsed, skip dose and resume at next regularly scheduled time.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992278"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the pharmacokinetics of tibolone and its metabolites are not dependent upon renal function.</p></div>
<div class="block doha drugH1Div" id="F50989513"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with liver dysfunction or disease.</p></div>
<div class="block doe drugH1Div" id="F20321381"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F20321349"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Genital pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Lower abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal cervical or vaginal Papanicolaou smear, breast tenderness, cervical dysplasia, endometrial hyperplasia, genital discharge, pelvic pain, vaginal discharge, vaginal hemorrhage, vulvovaginal candidiasis, vulvovaginitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection, vaginal mycosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Nipple pain</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cerebrovascular accident, deep vein thrombosis, ischemic stroke, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased glucose tolerance, decreased HDL cholesterol, decreased LDL cholesterol (decrease in VLDL), decreased serum cholesterol, decreased serum triglycerides, decreased thyroxine binding globulin, decreased total T4, lipid metabolism disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased sex hormone binding globulin, endometrial carcinoma, malignant neoplasm of breast</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Seborrheic dermatitis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, dizziness, headache, migraine</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal disease (including arthralgia and myalgia)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, visual disturbance</p></div>
<div class="block coi drugH1Div" id="F20321346"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tibolone or any component of the formulation; liver dysfunction or disease; known or suspected estrogen-dependent or progestin-dependent malignant neoplasia (eg, endometrial cancer); endometrial hyperplasia (including untreated); known, suspected, or past history of breast cancer; undiagnosed abnormal genital bleeding; known or suspected pregnancy and lactation; active or past history of arterial thromboembolic disease (eg, angina, stroke, myocardial infarction, coronary heart disease, transient ischemic attack); active or past history of confirmed venous thromboembolism (such as deep venous thrombosis or pulmonary embolism) or active thrombophlebitis; known thrombophilic disorders (eg, protein C, protein S, antithrombin deficiency); partial or complete loss of vision due to ophthalmic vascular diseases; porphyria.</p></div>
<div class="block war drugH1Div" id="F20321347"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: <b>[Canadian Boxed Warning]: May increase the risk of breast cancer and can be dependent on individual risk factors. Based on data from the Women's Health Initiative (WHI) trial, an increased risk of invasive breast cancer may be associated with estrogen plus progestin use.</b> The Million Women Study (MWS) also found an increased risk of breast cancer in association with tibolone therapy; risk returned to baseline within a few (≤5) years of stopping tibolone therapy. Use with caution in patients at risk for estrogen-dependent tumors (eg, strong family history, breast conditions with increased risk). Patients should receive a mammogram prior starting therapy and at regular intervals during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: <b>[Canadian Boxed Warning]: Based on data from the WHI trial, an increased risk of invasive myocardial infarction (MI) may be associated with estrogen plus progestin use. </b>Tibolone has not been shown to protect against MI in women with or without existing coronary artery disease (CAD). In general, use of combined estrogen-progestogen menopausal hormone therapy (MHT) is associated with slight increase of CAD in patients &gt;60 years of age; use caution with tibolone in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: MHT does not improve cognitive function; risk of dementia may increase with some MHT when initiated in patients &gt;65 years of age; use caution with tibolone in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial carcinoma/hyperplasia: <b>[</b>
<b>Canadian Boxed Warning]: May increase the risk of endometrial cancer in patients with an intact uterus and can be dependent on individual risk factors. </b>Tibolone increases endometrial wall thickness. Breakthrough bleeding/spotting that occurs ≥6 months after initiation of therapy warrants referral for gynecologic evaluation. Investigate any irregular/unscheduled vaginal bleeding to rule out malignancy prior to tibolone initiation. Use caution in patients with a history of endometrial hyperplasia; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ischemic stroke: <b>[Canadian Boxed Warning]: May increase the risk of stroke and can be dependent on individual risk factors. Based on data from the WHI trial, an increased risk of stroke may be associated with estrogen use or estrogen plus progestin use.</b> Effect may be greater in older (&gt;60 years of age) patients. Discontinue therapy in patients who develop classical migraine, loss of consciousness, paralysis, transient aphasia, or visual disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid abnormalities: Cases of hypertriglyceridemia resulting in pancreatitis have been (rarely) reported with estrogen replacement therapy; use caution in women with preexisting hypertriglyceridemia. Other changes in lipid profiles, including dose-dependent reductions in high-density lipoprotein cholesterol, were observed with tibolone use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. In the MWS, the relative risk for ovarian cancer with tibolone use was similar to other types of MHT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b> [Canadian Boxed Warning]: Based on data from the WHI trial, an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) may be associated with estrogen use or estrogen plus progestin use.</b> Risk is increased during the first year of therapy. Discontinue therapy promptly if venous thromboembolism (VTE) occurs. Use caution in patients with thromboembolic risk factors. Screening for thrombophilic defects may be offered to patients with family history (eg, first-degree relative) of early thrombosis. Before and during treatment, assess individual patient risk factors for VTE (age, obesity, immobilization/surgery, systemic lupus erythematosus [SLE], cancer). Use tibolone with caution in patients on anticoagulation therapy for any reason.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Carbohydrate intolerance: Use caution in patients with diabetes, with or without vascular involvement; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: <b>[Canadian Boxed Warning]: Estrogens with or without progestins should not be prescribed for primary or secondary prevention of cardiovascular disease. </b>Use caution in hypertensive patients; may exacerbate disease. Discontinue therapy if significant increase in BP occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution in patients with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallstones: Use caution in patients with gallstones; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic disease: Use caution in patients with hepatic disorders (eg, adenoma); may exacerbate disease. Discontinue therapy if jaundice or abnormal hepatic function occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Estrogens may induce or exacerbate symptoms in women with hereditary angioedema. Discontinuation of therapy may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic/endocrine diseases: Careful evaluation is recommended prior to starting therapy in patients with metabolic or endocrine diseases and when metabolism of calcium and phosphorus is abnormal; monitor regularly as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution in patients with migraines or severe headaches; may exacerbate condition. Discontinue if new-onset migraine-type headache occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Otosclerosis: Use caution in patients with otosclerosis; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematous: Use caution in patients with SLE; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Uterine abnormalities: Use caution in patients with leiomyoma (uterine fibroids) or endometriosis; may exacerbate these conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: May contain lactose; do not use with galactose intolerance, congenital lactase deficiency, or glucose-galactose malabsorption syndromes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Administer only to patients with an intact uterus. <b>[Canadian Boxed Warning]: A complete personal and family medical history should be taken before starting treatment. Periodic check-ups are recommended while on treatment. </b>Not intended for combined hormone therapy; a separate progestogen should <b>not</b> be added to tibolone therapy. Treatment should be reserved for symptoms that adversely affect quality of life. Not intended for contraceptive use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits:<b> [Canadian boxed warning]: The WHI trial examined the health benefits and risks of oral combined estrogen plus progestin therapy (n=16,608) and oral estrogen-alone therapy (n=10,739) in postmenopausal women 50 to 79 years of age. The estrogen plus progestin arm of the WHI trial (mean age 63.3 years) indicated an increased risk of MI, stroke, invasive breast cancer, PE, and DVT in postmenopausal women receiving treatment with combined conjugated equine estrogens (CEE) (0.625 mg/day) and medroxyprogesterone acetate (2.5 mg/day) for 5.2 years compared to those receiving placebo. The estrogen-alone arm of the WHI trial (mean age 63.6 years) indicated an increased risk of stroke and DVT in hysterectomized women treated with CEE alone (0.625 mg/day) for 6.8 years compared to those receiving placebo.</b> Based on data from the WHI trial,<b> estrogens with or without progestins should be prescribed at the lowest effective dose and the shortest period possible for the approved indication.</b> Tibolone treatment should continue only as long as benefits outweigh the risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery patients: If prolonged immobilization is expected following elective surgery, interrupt tibolone therapy 4 to 6 weeks prior to surgery and restart only when patient is fully mobile.</p></div>
<div class="block prod-avail drugH1Div" id="F20321387"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block dinfoc drugH1Div" id="F54858526"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tibella: 2.5 mg</p></div>
<div class="block adm drugH1Div" id="F20321384"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at the same time each day without regard to meals. Swallow tablet whole with water/fluid.</p></div>
<div class="block hazard drugH1Div" id="F49161164"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]). </p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F20321342"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Vasomotor symptoms associated with menopause:</b> Short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal patients, &gt;1 year after menopause.</p></div>
<div class="block mst drugH1Div" id="F54754547"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">
<b>ALERT: [Canadian Boxed Warning]:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F20797325"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F20797323"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Tibolone may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F20321343"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Tibolone is approved for use post menopause; use is contraindicated during pregnancy. Discontinue immediately if pregnancy occurs.</p></div>
<div class="block brc drugH1Div" id="F20321345"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tibolone or its metabolites are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Use is contraindicated in patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F20321386"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Routine physical examination that includes family medical history and BP; breasts and pelvic exam are recommended, including a Papanicolaou smear. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Baseline mammography, blood serum glucose, serum calcium, triglycerides and cholesterol levels, and LFTs. Monitor for signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy. Assess need for therapy 3 to 6 months after initiation.</p></div>
<div class="block pha drugH1Div" id="F20321359"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tibolone itself is pharmacologically inactive; it is converted to 3 active metabolites with estrogenic, progestogenic, and androgenic properties. It substitutes for estrogen loss in postmenopausal women and decreases vasomotor symptoms of menopause.</p></div>
<div class="block phk drugH1Div" id="F20321361"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly converted in the GI tract and liver into 3 active metabolites (3α-OH-tibolone [estrogenic], 3β-OH-tibolone [estrogenic], and delta-4-isomer of tibolone [progestogenic/androgenic]).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3α/3β -OH-tibolone: 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tibolone and active metabolites: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (major route; as metabolites); urine (minor route; as metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059531"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Climalona | Climatix | Discretal | Klimastress | Paraclim | Senalina | Tiboclim Plb | Tibofem | Tocline</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Liviel | Tiloria</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo tibolone | Livial | Livilan | Tibolone lupin | Tibolone sandoz | Xyvion</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lenea | Livial | Menorest | Renorma | Tibilone | Tibo | Tibofem | Tibonor | Tivion | Ubilon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Heria | Livial | Sempreluna | Tibolinia | Tibolone gedeon richter</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clindella | Klimater | Libiam | Livial | Livolon | Reduclim | Tibial | Tiboclin | Tibolona | Tiloger | Tilogran</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Livial | Marysa | Tibolon mepha | Tibolon sandoz | Tibolon spirig hc</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Climafem | Climaval | Lifar | Lirex | Livial | Plenovid | Reduclim | Tinox | Tobe</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Livial | Zi zhu ai wei | Zizhu ai wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Flart | Livial | Tibonella | Tinox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial | Tibolon aristo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Livial | Liviella | Tibelia | Tibolon aristo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Climabel | Libona | Livial | Paraclim | Pauxa | Tibonella | Tiborec</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Climafen | Climatibol | Livial | Menotrix | Menox | Paraclim | Tibolona genamerica | Tibolux | Tibonella</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hansas | Livial | Oestrolone | Tibolian</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Boltin | Tibicare | Tibocina | Tibolona aristo | Tilia</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibelia | Tibocina | Tibolon Orifarm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibolone ccd | Tibolone mylan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibolone/Teva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Clitax | Livial | Menorest</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial | Tibelia</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Livial | Maxtib | Rigold | Sibolone | Tibofem | Tibomax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Livial | Shyla | Tibocina | Tibolone aristo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibol | Tibon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hyundai tibolone | Libolone | Libron | Livial | Pharmbio korea tibolone | Rabilone | Ribi m | Riveon | Tibiol | Tibolan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Heria | Livial | Sempreluna</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ladybone | Livial</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Analobit | Bonavax | Bontil | Lisertil | Livial | Menivial | Sintemel | Tibolona | Tibolona landsteiner</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Livial | Menorest | Tiboleen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Boltin | Livial | Tibolinia | Tibolon | Tibolon mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibolon aristo | Tibolon Orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Femenil a | Livial | Neotilom | Sintemel | Tibogyn | Tibolona | Tibolux | Tibomax | Tibona | Tinox | Torbonal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amena | Livial | Tiboleen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Livial | Lobion Hrt | Tebisol | Tibofem | Tibogen | Tibol | Tibopause</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial | Tibolone aristo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Clitax | Goldar | Livial | Tibolona aristo | Tibolona zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tobe</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial | Velledien</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibofem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibelia | Tibocina | Tibolon aristo | Tibolon mylan | Tibolon Orifarm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ladybon | Livial | Tibolon aristo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Livial</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Livial | Tibelia</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Espa tibol | Livial</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Paraclim | Tibofem | Tibolona | Tibona</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Climabel | Femsel | Fomene | Livial | Paraclim | Renorma | Tibozak | Tinox</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Livifem | Tibolone actor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18703472">
<a name="18703472"></a>Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. <i>N Engl J Med.</i> 2008;359(7):697-708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tibolone-united-states-not-available-drug-information/abstract-text/18703472/pubmed" id="18703472" target="_blank">18703472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27733017">
<a name="27733017"></a>Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. <i>Cochrane Database Syst Rev</i>. 2016;10(10):CD008536. doi:10.1002/14651858.CD008536.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tibolone-united-states-not-available-drug-information/abstract-text/27733017/pubmed" id="27733017" target="_blank">27733017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19167925">
<a name="19167925"></a>Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. <i>Lancet Oncol. </i>2009;10(2):135-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tibolone-united-states-not-available-drug-information/abstract-text/19167925/pubmed" id="19167925" target="_blank">19167925</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tibella (tibolone) [product monograph]. Mississauga, Ontario, Canada: BioSyent Pharma Inc; May 2022.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed July 31, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129317 Version 42.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
